Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
Journal: Science translational medicine
Published: July 29, 2026
Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
Journal: Lancet (London, England)
Published: June 10, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 30, 2026
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.
Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: October 13, 2025
Genomics Define Malignant Transformation in Myeloma Precursor Conditions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 08, 2025
Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: September 16, 2025
Last Updated: 09/26/2026